Hematology · 2 h ago
EHA guideline updates follicular lymphoma diagnosis and treatment
The European Hematology Association guideline summarizes evidence-based recommendations for diagnosis, staging, treatment and follow-up of newly diagnosed and relapsed follicular lymphoma. It outlines different approaches according to disease extent, tumor burden and relapse history.
- Diagnosis requires adequate biopsy and specialist pathology review.
- Treatment choices depend on extent, tumor burden and relapse history.
- Follow-up and shared decision-making are emphasized.
Follicular lymphoma is an indolent but heterogeneous disease, with median overall survival at diagnosis now likely exceeding 20 years, according to the guideline. Diagnosis requires adequate biopsy material and review by a specialized hematopathologist; staging and prognosis rely on PET-CT and validated clinical scores.
For localized disease, the guideline describes radiotherapy, with or without rituximab. For disseminated disease, active surveillance or, in selected low-tumor-burden cases, rituximab monotherapy are options; high-tumor-burden disease is most often treated with immunochemotherapy, with selected chemotherapy-free options and possible antibody maintenance. At relapse, the recommendations prioritize rituximab-lenalidomide, with or without tafasitamab or epcoritamab, from first relapse; after a second relapse, options include bispecific antibodies, CAR-T cells and zanubrutinib-obinutuzumab.
The guideline also emphasizes careful follow-up and patient involvement in decisions. The source provides only an abstract, so it does not include the underlying evidence grading, detailed eligibility criteria or full treatment algorithms; those details should be checked in the full guideline before applying specific recommendations.
In practice
For clinicians managing follicular lymphoma, the guideline differentiates treatment by disease extent, tumor burden and relapse history: localized disease is usually treated with radiotherapy with or without rituximab; selected patients with low-burden disseminated disease may be observed or receive rituximab alone, while high-burden disease is usually treated with immunochemotherapy. It prioritizes specified targeted and cellular options at relapse. These are guideline recommendations, but the supplied abstract lacks evidence grading and detailed criteria, so it is insufficient to establish patient-specific eligibility or a change in practice by itself.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
HemaSphere: Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.